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Two Randomized Trials of the Effect of Live Attenuated
Inﬂuenza Vaccine on Pneumococcal Colonization
To the Editor:
The human nasopharynx is frequently colonized by Streptococcus
pneumoniae (the pneumococcus), serving as the reservoir
for transmission, a state that necessarily precedes invasive
pneumococcal infection. Inﬂuenza infection increases
pneumococcal colonization density and dysregulates host immune
responses, increasing the risk of secondary bacterial pneumonia
and death (1–3).
Live attenuated inﬂuenza vaccine (LAIV) nasal spray has
been used in the United States since 2003, and it has reduced
severe inﬂuenza disease in the United Kingdom since its introduction
in 2013 into the national pediatric immunization program. In
mice, LAIV vaccination increases the density and duration of
pneumococcal colonization (2) and rates of otitis media. In
children, LAIV is associated with increased rates and density of
bacterial colonization (4). Although LAIV is safe and not associated
with increases in pneumococcal disease, these data suggest that
it could increase pneumococcal transmission to susceptible
individuals (5).
We therefore undertook two trials (EudraCT 2014-004634-26)
using an established human challenge model to evaluate the effects
of LAIV on the dynamics of pneumococcal colonization. Some
of the results of these studies have been previously reported in the
form of a preprint (https://doi.org/10.1101/343319). An extensive
immunological investigation to accompany these clinical data has
been published (6). Healthy nonsmoking volunteers, 18–50 years
old, consented to participate in double-blinded, randomized,
placebo-controlled trials reﬂecting alternative scenarios:
1) immunization ﬁrst (LAIV precedes nasopharyngeal inoculation
with pneumococcus by 3 days) and 2) colonization ﬁrst (LAIV is
administered 3 days after colonization with pneumococcus). The
participants, who were uncolonized at baseline, randomly received
either intervention (nasal LAIV paired with intramuscular placebo
of normal saline; AstraZeneca) or control (nasal placebo of normal
saline paired with intramuscular inﬂuenza vaccination [Fluarix
Tetra; GlaxoSmithKline]) with concealment by blindfolding.
All of the participants gave written informed consent, with
approval from the North West NHS Research Ethics Committee
(14/NW/1460).
All of the participants were inoculated with S. pneumoniae serotype
6B strain BHN418 (80,000 cfu per nostril) in 0.1 ml solution (7). (The
S. pneumoniae BHN418 sequence [GI:557376079] is available from
https://www.ncbi.nlm.nih.gov/nuccore/557376079). “Colonization
positivity” was determined by serial nasal washes and deﬁned
by detection of serotype 6B by culture at a programmed time
point from 2 to 29 days (7, 8). In parallel, PCR detection of
pneumococcal lytA was performed. In the “immunization ﬁrst”
study, LAIV vaccination preceded pneumococcal inoculation by
3 days (primary endpoint: colonization rate). This order was
reversed for the “colonization ﬁrst” study (primary endpoint: area
under the curve [AUC] of bacterial density between Days 2 and
14). Results are presented as modiﬁed intention to treat, excluding
those who did not receive immunization or inoculation per
protocol, or did not complete follow-up. Generalized linear models
were used to compare colonization positivity, duration of
colonization, and AUC bacterial density, with generalized
estimating equations used for comparison at multiple time points.
Full methodological and other details are available online in the
form of a preprint (https://doi.org/10.1101/343319).
In the “immunization ﬁrst” study (Figure 1), we enrolled 202
participants; 130 of these subjects were inoculated and 117 were
analyzed (n = 55 LAIV, n = 62 control; overall mean age, 20 yr [range,
18–48 yr]; 58% female). Pneumococcal colonization rates were
similar in LAIV participants and control subjects (25/55 [45.5%]
vs. 24/62 [38.7%]; odds ratio [OR], 1.32; P = 0.46), although the
LAIV-treated group had consistently yet nonsigniﬁcantly higher
rates at each time point. PCR detection rates were signiﬁcantly
higher in the LAIV group than in the control group at Day 2 (33/55
[60.0%] vs. 25/62 [40.3%]; OR, 2.22; P = 0.03). The median
duration of colonization was not different between the groups by
conventional microbiology (22 d [interquartile range (IQR), 22–29]
and 22 d [IQR, 14–29] in the LAIV and control groups,
respectively; P = 0.09) or PCR (median, 22 d [IQR, 7–29] LAIV vs.
14 d [IQR, 7–22] control; P = 0.45). Mean colonization densities
were consistently increased in the LAIV group, with statistical
signiﬁcance at Day 9 representing a 10-fold (1 log10) increase in
colonization density in the LAIV group (2.826 1.78 vs. 1.816 1.39
log10 titers, P = 0.03; Figure 1). PCR results showed the same
pattern, with signiﬁcantly higher densities in the LAIV group at
Day 2 (P = 0.03).
Four participants with laboratory-conﬁrmed other viral
infections (three inﬂuenza B in the control arm, one rhinovirus in the
LAIV arm) had among the highest bacterial densities of their
cohorts. Among pneumococcal-colonized individuals, the AUC of
colonization density was higher in the LAIV group than in the control
group, with borderline statistical signiﬁcance at Days 2–14 (P = 0.05),
and reached statistical signiﬁcance after exclusion of participants who
had nasal-swab PCR evidence of concurrent wild-type viral illness
(three inﬂuenza B in the control arm, one rhinovirus in the LAIV
arm; data not shown; P = 0.03) after presenting with symptoms of
illness.
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In the “colonization ﬁrst” study (Figure 2), 316 participants
consented, 206 were screened, and 163 participants were included
in the modiﬁed intention-to-treat analysis (n = 73 LAIV, n = 90
control; overall mean age, 20 yr [range, 18–46 yr]; 55% female).
Data from 17 participants (10%) were excluded owing to non-
study-serotype S. pneumoniae colonization. AUC colonization
densities for each time period were consistently lower in the LAIV
group, although the difference was not statistically signiﬁcant
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Figure 1. Immunization first: live attenuated influenza vaccine (LAIV) precedes nasopharyngeal inoculation with pneumococcus—effect on colonization
dynamics of LAIV vaccination given at Day 23. Density dynamics after pneumococcal inoculation (on Day 0) are calculated from classical microbiology
[log10(cfu/ml1 1)]. Mean density of Streptococcus pneumoniae for each nasal wash time point among participants in whom serotype 6B was detectable
at any point. Bars represent SE. Inset: area under the curve (AUC) of density–time from Day 2 to Day 14 (box plot of median with interquartile range, with
whiskers at 1.53 the interquartile range). *Statistically significant difference (P , 0.05).
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Figure 2. Colonization first: live attenuated influenza vaccine (LAIV) is administered to subjects already inoculated with pneumococcus—effect on
colonization dynamics. Experimental inoculation to pneumococcus was performed on Day 23. Density dynamics after LAIV vaccination or control (on Day 0)
are calculated from classical microbiology [log10(cfu/ml1 1)]. Mean density of Streptococcus pneumoniae for each nasal wash time point among
participants in whom serotype 6B was detectable at any point. Bars represent SE. Inset: area under the curve (AUC) of density–time from Day 2 to Day 14
(the primary endpoint, box plot of median with interquartile range, with whiskers at 1.53 the interquartile range).
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(P = 0.11 for Days 2–14 primary endpoint; Figure 2). By PCR, a
signiﬁcantly lower AUC was evident in the LAIV group compared
with the control group on Days 2–27 (P = 0.03).
Rates of colonization did not differ between the LAIV and
control groups by conventional microbiology (36/73 [49.3%] vs.
45/90 [50.0%] respectively; OR, 0.97; P = 0.93). The median
colonization duration did not differ between the two groups
(21 vs. 27 d, P = 0.17) by conventional microbiology, although it
was lower in the LAIV group by PCR (14 vs. 27 d, P = 0.001).
There were no serious adverse events related to the intervention
in either study.
In the largest trial to date involving a controlled human
coinfection model, we have studied for the ﬁrst time the impact
of coinfection of a live viral vaccine and a bacterial pathogen.
Immunological parameters have been reported separately (6).
Antecedent LAIV administration caused modest but signiﬁcant
transient effects on pneumococcal colonization, in keeping with a
pediatric randomized controlled trial that showed an increased
pneumococcal density after LAIV (2). In our study, the inverse
scenario (LAIV after pneumococcal colonization) was associated
with reduced colonization density and colonization rates at Day 27,
decreased AUC, and earlier bacterial clearance.
Our model, consistent with murine coinfection disease models,
reinforces the notion that the precedence of pathogen exposure
might determine disease outcome: pneumococcal infection after
inﬂuenza might exacerbate disease, whereas pneumococcus
infection preceding inﬂuenza might reduce mortality (9). We used
complementary methods for bacterial detection: although PCR is
more sensitive and could detect DNA in the absence of viable
pathogen, the persistence beyond 2 days suggests lower-density
colonization, which is unmeasurable by culture.
These studies were limited by size and the evaluation of a single
pneumococcal serotype in healthy adults likely to have neutralizing
inﬂuenza antibodies. Any effect of LAIV in children may therefore be
more pronounced owing to lower antibody titers, increased viral shedding,
and higher natural rates of pneumococcal colonization acquisition. Future
vaccine studies should evaluate the effect on pathogens not directly
targeted by the vaccine, including their onward transmission. n
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Right Ventricular Load and Function in Chronic
Thromboembolic Pulmonary Hypertension:
Differences between Proximal and Distal Chronic
Thromboembolic Pulmonary Hypertension
To the Editor:
The clinical presentation of chronic thromboembolic
pulmonary hypertension (CTEPH) ranges from central pulmonary
obstruction to more peripheral obstruction and small vessel
vasculopathy. Location of CTEPH lesions does not seem to inﬂuence
pulmonary artery pressures (1, 2), but its effect on right ventricular
(RV) load and function is currently unknown. In this retrospective
analysis, we aimed to determine the inﬂuence of proximal and
distal vascular lesions on RV afterload and function, integrating
static and pulsatile components of afterload and RV function
parameters.
Methods
Seventy-ﬁve patients from our clinical registry were selected on the
basis of the presence of high-quality computed tomography–
pulmonary angiography, right heart catheterization (RHC), and
cardiac magnetic resonance (CMR) imaging before initiation of
treatment (maximum interval between investigations was 6 mo).
According to computed tomography–pulmonary angiography,
CTEPH was classiﬁed as either proximal (level I/II disease:
lesions starting in the main or lobar arteries) or distal (level III–IV
disease: lesions starting in the segmental and subsegmental) (3) for
each side separately. Twenty-nine patients with asymmetrical lesions
(proximal on one side and distal on the other side) were not included
in the ﬁnal analysis.
RHC and CMR were performed and analyzed as previously
described (4):
d Pulmonary artery (PA) pulse pressure (mm Hg) = systolic
pulmonary artery pressure (PAP)2 diastolic PAP
d PA compliance (ml/mm Hg) = ( _Q/heart rate)/pulse pressure
d Resistance–compliance (RC) time (s) = 0.75 $ 1023 $ pulmonary
vascular resistance (PVR, dyn $ s $ cm25) $ compliance
This retrospective study did not fall within the scope of the
Medical Research Involving Human Subjects Act, as conﬁrmed by
the Medical Ethics Review Committee of the VUUniversity Medical
Center (2017.025).
Table 1. Baseline Characteristics, Hemodynamic and Cardiac Magnetic Resonance Proﬁle
Variable Proximal CTEPH (n = 21) Distal CTEPH (n = 25) P Value
Age, yr 65 (50–70) 66 (52–73) 0.723
Male, n (%) 13 (62) 11 (44) 0.226
6MWD, m 339 (71), n = 19 445 (108), n = 19 0.001*
NT-proBNP, ng/L 1,745 (549–4,185) 446 (150–1,360) 0.032*
DLCO, % predicted 61.9 (13.8), n = 18 75.7 (13.5), n = 19 0.004*
Right heart catheterization
mPAP, mm Hg 49.1 (12.3) 45.5 (10.2) 0.286
PAWP, mm Hg 9.7 (4.3) 11.8 (2.7) 0.058
PVR, dyn $ s $ cm25 740 (544–1,011) 555 (419–775), n = 24 0.162
CI, L/min/m2 2.1 (0.4) 2.4 (0.6), n = 24 0.077
mRAP, mm Hg 11.6 (5.3), n = 18 8.2 (2.9) 0.010*
PA pulse pressure, mm Hg 52.8 (15.8) 47.9 (11.6) 0.234
Stroke volume, ml 54.8 (19.6) 64.3 (22.9), n = 22 0.150
Heart rate, beats/min 80 (71–88) 73 (63–81), n = 22 0.088
Compliance, ml/mm Hg 1.11 (0.64–1.31) 1.34 (0.80–1.89), n = 22 0.098
Cardiac magnetic resonance
RVEF, % 34.1 (12.9) 44.7 (15.2) 0.015*
RVEDVI, ml/m2 95.3 (26.2) 80.5 (21.4) 0.041*
LVEF, % 59.8 (9.3) 66.9 (10.1) 0.018*
LVEDVI, ml/m2 54.2 (14.4) 53.5 (13.6) 0.873
SVI, ml/m2 29.9 (6.1) 33.6 (9.1), n = 24 0.120
Definition of abbreviations: 6MWD= 6-minute-walk distance; CI = cardiac index; CTEPH = chronic thromboembolic pulmonary hypertension; LVEDVI = left
ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; mPAP =mean pulmonary artery pressure; mRAP =mean right atrial
pressure; NT-proBNP = N-terminal pro–brain natriuretic peptide; PA = pulmonary artery; PAWP= pulmonary artery wedge pressure; PVR = pulmonary
vascular resistance; RVEDVI = right ventricular end-diastolic volume index; RVEF = right ventricular ejection fraction; SVI = stroke volume index.
Data are presented as mean (SD), median (interquartile range), or number of patients (%). Data apply to all 21 and 25 patients per group unless otherwise
stated. Statistical tests: unpaired t test, chi-square test, Fisher’s exact test, and Mann-Whitney test.
*Statistical significance.
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